

**Pharmacy and Therapeutics Advisory Committee Recommendations**

March 16, 2006 Meeting

This chart provides a summary of the final PDL selections that were made by the Secretary for Health and Family Services as a result of the Pharmacy and Therapeutics Advisory Committee meeting of March 16, 2006.

	Description of Recommendation	Final PDL Decision
#1	<p><b>Insulin</b></p> <ol style="list-style-type: none"> <li>1. The insulin agents are considered clinically equivalent in safety and efficacy.</li> <li>2. DMS to prefer one brand of human insulin per class (basal long-acting, rapid-acting, and short-acting, insulin for use in pumps, mixed preparations and insulin delivery systems) based upon economic evaluation.</li> <li>3. Lantus will be retained as a preferred basal long-acting insulin with the option to add other products in the class based upon economic evaluation.</li> <li>4. Recommendations on Exubera to be tabled for review at a future meeting.</li> <li>5. Byetta will require PA via electronic step-edit.</li> <li>6. Symlin will require PA.</li> <li>7. DMS to require PA for pen delivery systems for patients unable to manipulate vials/syringes (eyesight, dexterity, comprehension).</li> <li>8. For any new chemical entity in the insulin class, require a PA until reviewed by the P &amp; T Advisory Committee.</li> </ol>	<p>Recommendations Approved</p> <p><u>PDL Selections</u>            NOVOLOG            NOVOLOG mix 70/30            NOVOLIN 70/30            NOVOLIN N            NOVOLIN R</p> <p>LANTUS            LEVEMIR</p>
#2	<p><b>Flouroquinolones</b></p> <ol style="list-style-type: none"> <li>1. All agents in the quinolone class are equivalent in efficacy within generations.</li> <li>2. DMS to prefer generic 2<sup>nd</sup> generation quinolones.</li> <li>3. Branded 2<sup>nd</sup> generation quinolones will require PA.</li> <li>4. DMS to prefer two branded 3<sup>rd</sup> generation quinolones, one of which must be either Avelox <u>or</u> Levaquin and the other to be preferred based upon economic evaluation.</li> <li>5. If Tequin is selected as a preferred 3<sup>rd</sup> generation quinolone, a diabetes safety edit must be implemented.</li> <li>6. For any new chemical entity in the quinolone class, require a PA until reviewed by the P&amp;T Advisory Committee.</li> </ol>	<p>Recommendations for the Flouroquinolones are under review</p>

Kentucky Department for Medicaid Services

# Pharmacy and Therapeutics Advisory Committee Recommendations

March 16, 2006 Meeting